Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CorMedix Inc (CRMD) vs Prime Medicine, Inc. (PRME)

CorMedix Inc and Prime Medicine, Inc. are both Biotechnology companies. CorMedix Inc and Prime Medicine, Inc. are of similar size ($609.4M and $608.0M). Prime Medicine, Inc. has negative trailing earnings, so its P/E is not meaningful; CorMedix Inc trades at 3.3×. CorMedix Inc grew revenue faster over the last twelve months: 280.5% against −17.9%. CorMedix Inc has the higher net margin (40.5% vs −4,613.1%) and the higher return on invested capital (38.8% vs 0.00%). Across the 17 metrics below, CorMedix Inc leads on 14 and Prime Medicine, Inc. on 3.

Valuation

Metric CRMD PRME Biotechnology median
P/E 3.26 n/m 7.88
P/S 1.33 126.19 11.47
P/B 1.34 12.91 2.52
Price to free cash flow 2.46 n/m 21.16
EV/EBITDA 1.99 n/m 0.74
EV/Sales 1.09 102.84 10.73
Earnings yield 30.70% (37.01%) (28.84%)
Free cash flow yield 40.67% (30.52%) (23.03%)

Profitability

Metric CRMD PRME Biotechnology median
Gross margin 82.78% 100.00% 65.16%
Operating margin 46.95% (4,824.94%) 0.00%
Net margin 40.49% (4,613.11%) 0.00%
Free cash flow margin 54.17% (3,850.92%) 0.00%
Return on equity 54.93% (373.29%) (57.72%)
Return on assets 32.36% (71.16%) (49.22%)
Return on invested capital 38.84% 0.00% 0.00%

Growth

Metric CRMD PRME Biotechnology median
Revenue growth (TTM) 280.50% (17.90%) 5.64%
EPS growth (last fiscal year) 780.00% 18.18% —
Revenue growth, 5-year CAGR 305.79% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRMD PRME Biotechnology median
Debt to equity 0.32 0.00 0.00
Current ratio 2.56 3.05 4.73
Net debt to EBITDA (0.02) 0.88 0.96

Dividend

Metric CRMD PRME Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric CRMD PRME Biotechnology median
Market cap 607.97m 609.43m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack